Al Kildani, Senior Vice President of Investor Relations and Corporate Communications, Acadia Pharmaceuticals : Good afternoon, and thank you for joining us on today's call to discuss Acadia's first quarter twenty twenty five financial results. Joining me on the call today from Acadia are Catherine Owen Adams, our Chief Executive Officer, who will provide some opening remarks followed by Tom Garner, our Chief Commercial Officer, who will discuss our strong commercial brands, Debut and NUPLAZID. Also joining us today is Elizabeth Thompson, PhD, Executive Vice President, Head of Research and Development, who will provide an update on our pipeline programs, and Mark Schneier, our Chief Financial Officer, will review the financial highlights. Kathryn will then provide some closing thoughts before we open up the call for your questions. We are using supplemental slides, which are available on our website Events and Presentations section.